Hematology
Conference Coverage
HIT risk rises with obesity
Higher body mass index is strongly associated with increased rates of heparin-induced thrombocytopenia
Clinical Review
Dyspnea in Malignancy
Accounting for 3 to 4 million ED visits annually, this conditionis not only prevalent in oncologic patients, but typically intensifieswith disease...
Law & Medicine
Malpractice Counsel: Missed Preeclampsia
Commentaries on cases involving undiagnosed preeclampsia in a 24-year-old postpartum patient and subdural hematoma in a 59-year-old man with a...
News
FDA warns of disabling joint pain from DPP-4 inhibitors
Most patients developed symptoms within a month of beginning treatment; however, some patients had been on a DPP-4 inhibitor for as long as a year...
News
ED care pathway hastens febrile neutropenia therapy
Key clinical point: Instituting a care pathway hastened antibiotic administration in cancer patients with fever in the emergency department. Major...
News
Longer hospitalization after bariatric surgery ups readmission risk
Key clinical point: Short length of hospital stay after bariatric surgery was not a risk factor for readmission. Major finding: Patients who were...
News
NICE recommends rivaroxaban for acute coronary syndrome
Rivaroxaban is recommended in combination with aspirin plus clopidogrel or aspirin alone for prevention of atherothrombotic events in people who...
Case Reports
Case Report: The Hungry, Hungry Haustra: The Case of a Missing Feeding Tube
The authors present a previously unseen case of an intussuscepted Foley catheter in a 69-year-old man with a history of squamous cell carcinoma of...
News
Home VTE treatment with rivaroxaban safe and effective
Key clinical point: Home treatment with rivaroxaban for patients with a low-risk first deep vein thrombosis or pulmonary embolism is safe and...
News
Dicloxacillin may cut INR levels in warfarin users
The antibiotic dicloxacillin appears to markedly decrease INR levels in patients taking warfarin.
Conference Coverage
In PCI, switching clopidogrel nonresponders to prasugrel halved 2-year cardiac mortality
Switch clopidogrel nonresponders undergoing percutaneous coronary intervention to prasugrel to cut their 2-year cardiac mortality risk in half.